FNY Managed Accounts’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

FNY Managed Accounts’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-7,200	Closed	-$417K	–	869
2017 Q3	$417K	Buy	+7,200	New	+$776K	0.55%	44
2017 Q2	–	Sell	-60	Closed	-$6K	–	686
2017 Q1	$6K	Buy	+60	New	+$7K	0.02%	602
2015 Q4	–	Sell	-1,500	Closed	-$254K	–	403
2015 Q3	$249K	Buy	+1,500	New	+$330K	0.7%	36

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Managed Accounts's ICPT Position: Q4 2017 in Review

FNY Managed Accounts sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 7,200 shares — an estimated $417K sold.

FNY Managed Accounts first reported a position in ICPT in Q3 2015 and held it in 3 quarters. The position peaked at $417K in Q3 2017. 168 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

FNY Managed Accounts reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
FNY Managed Accounts sold 7,200 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $417K.
FNY Managed Accounts first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
FNY Managed Accounts's Intercept Pharmaceuticals, Inc. position peaked at $417K in Q3 2017.
168 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.